Medulloblastoma, a highly malignant primary brain tumor, predominantly affects children and poses significant challenges in cancer research. Advances in genetic and molecular profiling have revolutionized our understanding, revealing distinct subgroups with unique prognoses and therapeutic responses. Research focuses on identifying novel biomarkers for early detection and targeted therapies to improve survival rates while minimizing long-term side effects. Cutting-edge studies explore the tumor microenvironment, aiming to disrupt supportive cellular interactions that facilitate tumor growth. Immunotherapy, including checkpoint inhibitors and CAR-T cell therapy, is emerging as a promising approach. By leveraging these scientific advancements, researchers strive to develop more precise, less toxic treatments, offering hope for better outcomes in medulloblastoma patients.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China